BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, I

StreetInsider2023-04-26

BALA CYNWYD, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2330808366?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-04-26 00:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2330808366","market":"us","top_or_hot":-1,"title":"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, I","media":"StreetInsider","content":"<div>\n<p>BALA CYNWYD, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=21549362\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, I</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, I\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-26 00:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=21549362><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BALA CYNWYD, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=21549362\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=21549362","article_id":"2330808366","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2330808366","pubTimestamp":1682441220,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"BALA CYNWYD, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the follow","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","BK4211":"区域性银行","BK4196":"保健护理服务","APR":"Apria, Inc.","BK4082":"医疗保健设备","LABP":"Landos Biopharma, Inc.","TERN":"Terns Pharmaceuticals, Inc.","RXDX":"Prometheus Biosciences, Inc.","LHDX":"Lucira Health, Inc.","BOLT":"Bolt Biotherapeutics, Inc.","ONTF":"ON24, Inc.","SPPI":"Spectrum Pharmaceuticals","BK4563":"昨日强势股","CGEM":"Cullinan Therapeutics","BK4539":"次新股","BK4023":"应用软件","ISBC":"投资者银行","SANA":"Sana Biotechnology, Inc.","BK4191":"家用电器","CRCT":"Cricut, Inc."},"translate_title":"BRODSKY&SMITH股东最新情况：通知投资者以下调查：Spectrum Pharmaceuticals，Inc.（纳斯达克-SPPI）、BELLUS Health Inc.（纳斯达克-BLU）、Prometheus Biosciences，I","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BOLT":1,"TERN":1,"SPPI":1,"SANA":1,"RXDX":1,"ONTF":1,"LHDX":1,"LABP":1,"ISBC":1,"CRCT":1,"CGEM":1,"APR":1,"BLU":1},"content_text":"BALA CYNWYD, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you. Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI) Under the terms of the Merger Agreement, Spectrum will be acquired by Assertio Holdings, Inc. (“Assertio”) (Nasdaq - ASRT). Spectrum stockholders will receive a fixed exchange ratio of 0.1783 shares of Assertio common stock for each share of Spectrum common stock they own, implying an upfront value of $1.14 per Spectrum share (approximately $248 million) based on Assertio’s stock price on April 24, 2023. Additionally, Spectrum stockholders will receive one CVR per Spectrum share entitling them to receive up to an additional $0.20 per share in total (approximately $43 million), payable in cash or stock at Assertio’s election. Following the close of the transaction, Assertio stockholders will own approximately 65% of the combined company, and Spectrum stockholders will own approximately 35%, on a fully diluted basis.The investigation concerns whether the Spectrum Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Assertio is paying too little for the Company. Additional information can be found at https://www.brodskysmith.com/cases/spectrum-pharmaceuticals-inc-nasdaq-sppi/. BELLUS Health Inc (Nasdaq – BLU) Under the terms of the Merger Agreement, BELLUS will be acquired by GSK Plc (NYSE - GSK). BELLUS shareholders will receive $14.75 cash for each BELLUS common share, for a total equity value of approximately $2.0 billion. The investigation concerns whether the BELLUS Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether GSK Plc is paying too little for the Company. Additional information can be found at https://www.brodskysmith.com/cases/bellus-health-inc-nasdaq-blu/. Prometheus Biosciences, Inc. (Nasdaq – RXDX) Under the terms of the agreement, Prometheus will be acquired by Merck (NYSE - MRK). Prometheus shareholders will receive $200.00 cash for each Prometheus common share, for a total equity value of approximately $10.8 billion. The investigation concerns whether the Prometheus Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Merck is paying too little for the Company. Additional information can be found at https://www.brodskysmith.com/cases/prometheus-biosciences-inc-nasdaq-rxdx/. Univar Solutions Inc. (NYSE – UNVR) Under the terms of the agreement, Univar will be acquired by funds managed by affiliates of Apollo (NYSE – APO) (the “Apollo Funds”) in an all-cash transaction that values the Company at an enterprise value of approximately $8.1 billion. The agreement provides that Univar Solutions shareholders will receive $36.15 per share in cash. The investigation concerns whether the Univar Solutions Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Apollo Funds are paying too little for the Company. Additional information can be found at https://www.brodskysmith.com/cases/univar-solutions-inc-nyse-unvr/. Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2330808366"}